Patrick John Finn Sells 2,174 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,174 shares of Twist Bioscience stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88. Following the sale, the chief operating officer now owns 176,206 shares in the company, valued at $5,307,324.72. The sale was disclosed in a document filed with the SEC, which is available through this link.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total transaction of $16,108.08.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock opened at $31.54 on Friday. The company’s fifty day moving average is $34.76 and its two-hundred day moving average is $30.33. Twist Bioscience Co. has a 1 year low of $11.46 and a 1 year high of $43.21.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.03. The business had revenue of $71.50 million for the quarter, compared to the consensus estimate of $67.59 million. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The business’s quarterly revenue was up 31.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. On average, sell-side analysts anticipate that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in TWST. Harbor Capital Advisors Inc. boosted its holdings in shares of Twist Bioscience by 4.3% in the third quarter. Harbor Capital Advisors Inc. now owns 25,897 shares of the company’s stock valued at $525,000 after acquiring an additional 1,062 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Twist Bioscience by 23.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,617 shares of the company’s stock valued at $316,000 after purchasing an additional 2,933 shares during the period. Strs Ohio lifted its stake in shares of Twist Bioscience by 6.5% in the third quarter. Strs Ohio now owns 27,900 shares of the company’s stock valued at $565,000 after purchasing an additional 1,700 shares during the period. Rockland Trust Co. lifted its stake in shares of Twist Bioscience by 29.7% in the third quarter. Rockland Trust Co. now owns 38,500 shares of the company’s stock valued at $780,000 after purchasing an additional 8,808 shares during the period. Finally, TD Asset Management Inc lifted its stake in shares of Twist Bioscience by 137.7% in the third quarter. TD Asset Management Inc now owns 73,148 shares of the company’s stock valued at $1,482,000 after purchasing an additional 42,374 shares during the period.

Wall Street Analyst Weigh In

TWST has been the topic of several research analyst reports. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Barclays lowered their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. Finally, Scotiabank raised their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 5th.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.